Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
MRK Price Action
Last 7 days
-3.7%
Last 30 days
-4.6%
Last 90 days
-9.9%
Trailing 12 Months
-43.2%
MRK Stock Price
MRK RSI Chart
MRK Valuation
MRK Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
MRK Fundamentals
MRK Revenue
MRK Earnings
MRK Profitability
MRK Investor Care
MRK Alerts
The Good News
Merck's collaboration with Cyprumed is a significant positive step, granting access to innovative oral peptide delivery technology and the potential for substantial milestone payments, reflecting the company's commitment to advancing its product offerings (The Pharma Letter, https://www.thepharmaletter.com/cyprumed-inks-licensed-deal-with-merck-and-co). Analysts have maintained 'Buy' ratings from Guggenheim and Goldman Sachs, recognizing the long-term growth potential despite short-term challenges (Yahoo Finance, https://finance.yahoo.com/news/merck-nyse-mrk-secures-global-174624411.html).
The Bad News
Merck is facing serious headwinds, including a class action lawsuit due to alleged securities fraud, which has severely impacted investor confidence and caused a significant drop in stock value (Markets Insider, https://markets.businessinsider.com/news/stocks/mrk-lawsuit-alert-class-action-lawsuit-against-merck-company-1034575350). Additionally, concerns over governance and recent disappointing earnings performance have led to a negative outlook among investors (Yahoo Finance UK, https://uk.finance.yahoo.com/news/merck-nyse-mrk-faces-multiple-172317255.html).
Revenue & Growth
Revenue Breakdown
As of: Dec 31, 2024
Pharmaceutical
| |||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2025 | 63.9B | 0 | 0 | 0 |
| 2024 | 61.4B | 62.5B | 63.2B | 64.2B |
| 2023 | 57.9B | 58.3B | 59.3B | 60.1B |
| 2022 | 54.0B | 57.2B | 59.0B | 59.3B |
| 2021 | 41.0B | 43.0B | 45.2B | 48.7B |
| 2020 | 40.4B | 38.0B | 36.5B | 42.4B |
| 2019 | 43.1B | 44.4B | 46.0B | 39.1B |
| 2018 | 40.7B | 41.3B | 41.7B | 42.3B |
| 2017 | 39.9B | 40.0B | 39.8B | 40.1B |
| 2016 | 39.4B | 39.4B | 39.9B | 39.8B |
| 2015 | 41.4B | 40.2B | 39.8B | 39.5B |
| 2014 | 43.6B | 43.5B | 43.1B | 42.2B |
| 2013 | 46.2B | 44.9B | 44.5B | 44.0B |
| 2012 | 48.2B | 48.4B | 47.8B | 47.3B |
| 2011 | 46.1B | 47.0B | 47.8B | 48.0B |
| 2010 | 33.5B | 38.9B | 44.0B | 46.0B |
| 2009 | 24.6B | 25.6B | 27.0B | 27.4B |
| 2008 | 0 | 24.1B | 24.0B | 23.9B |
| 2007 | 0 | 0 | 0 | 24.2B |
Get all data in R, Python etc through our Historical Stock Data APIs
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
| CEO | Mr. Robert M. Davis J.D. |
|---|---|
| WEBSITE | merck.com |
| SECTOR | Healthcare |
| INDUSTRY | Drug Manufacturers General |
| EMPLOYEES | 65535 |
